MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jconrel.2025.01.008

Медицинская библиотека · Journal of controlled release : official journal of the Controlled Release Society · 2025

Hybrid prodrug nanoassembly for hypoxia-triggered immunogenic chemotherapy and immune modulation.

Zhang Beiyuan, Qin Chao, Wang Xue, Shen Chuanhong, Li Shuo, Liu Taiyu, Li Wenqing, Chen Zhaojie, Wang Yawen, Liu Lisha, Yin Lifang

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Tumor hypoxia is a critical driver of cancer progression, metastasis, and therapy resistance, posing significant challenges in effective cancer treatment. Hypoxia-activable prodrugs offer a promising strategy to target tumors in low-oxygen conditions, but their efficacy is often hindered by intrinsic properties and extrinsic cues. In this study, we developed a dual-prodrug nanoassembly system (CPPA) composed of a hypoxia-triggerable camptothecin (CPT)-based dimeric prodrug (CP) and a lipid-conjugated STAT3 antisense oligonucleotide (ASO) prodrug (PA), aiming to enhance tumor-targeted chemotherapy and overcome the immune evasion within the tumor microenvironment. The CPPA self-assemble into stable nanomicelle capable of co-delivering both agents directly to the tumor site, where the hypoxia-triggered release of CPT induces immunogenic cell death (ICD) while STAT3 inhibition enhances immune response. In murine breast cancer models, CPPA demonstrated superior therapeutic efficacy by improving tumor cell killing, promoting immune cell infiltration, and modulating the immunosuppressive tumor microenvironment. This combination therapy not only reversed drug resistance but also prevented the formation of the pre-metastatic niche, significantly inhibiting tumor progression and metastasis. These findings highlight the potential of CPPA as an effective strategy for enhancing cancer immunotherapy, offering a promising approach to address the complex challenges of tumor hypoxia, immune evasion, and resistance to chemotherapy.

Для цитирования: Zhang Beiyuan, Qin Chao, Wang Xue, Shen Chuanhong, Li Shuo, Liu Taiyu, Li Wenqing, Chen Zhaojie, Wang Yawen, Liu Lisha, Yin Lifang. Hybrid prodrug nanoassembly for hypoxia-triggered immunogenic chemotherapy and immune modulation.. Journal of controlled release : official journal of the Controlled Release Society. 2025. DOI: 10.1016/j.jconrel.2025.01.008.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.